[go: up one dir, main page]

MX2020008265A - Derivados farmaceuticos del anillo heterobiciclico 6,5. - Google Patents

Derivados farmaceuticos del anillo heterobiciclico 6,5.

Info

Publication number
MX2020008265A
MX2020008265A MX2020008265A MX2020008265A MX2020008265A MX 2020008265 A MX2020008265 A MX 2020008265A MX 2020008265 A MX2020008265 A MX 2020008265A MX 2020008265 A MX2020008265 A MX 2020008265A MX 2020008265 A MX2020008265 A MX 2020008265A
Authority
MX
Mexico
Prior art keywords
heterobicyclic ring
pharmaceutical
ring derivatives
sle
confined
Prior art date
Application number
MX2020008265A
Other languages
English (en)
Inventor
Jag Paul Heer
Robert James Townsend
Michal Sarah Hallside
Adam Peter Smalley
Cros Josep Llaveria
Benedicte Lallemand
Martin Alexander Lowe
Xianfu Li
Anthony John Richardson
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18157247.0A external-priority patent/EP3527209A1/en
Priority claimed from EP18184724.5A external-priority patent/EP3597642A1/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2020008265A publication Critical patent/MX2020008265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención se refiere a derivados del anillo heterobicíclico 6,5, a procesos para prepararlos, a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de afecciones inflamatorias ocasionadas por la activación de STING, tales como SLE y atrofia geográfica.
MX2020008265A 2018-02-16 2019-02-15 Derivados farmaceuticos del anillo heterobiciclico 6,5. MX2020008265A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18157247.0A EP3527209A1 (en) 2018-02-16 2018-02-16 Pharmaceutical 6,5 heterobicyclic ring derivatives
EP18184724.5A EP3597642A1 (en) 2018-07-20 2018-07-20 Pharmaceutical 6,5 heterobicyclic ring derivatives
PCT/EP2019/053893 WO2019158731A1 (en) 2018-02-16 2019-02-15 Pharmaceutical 6,5 heterobicyclic ring derivatives

Publications (1)

Publication Number Publication Date
MX2020008265A true MX2020008265A (es) 2020-09-21

Family

ID=65352042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008265A MX2020008265A (es) 2018-02-16 2019-02-15 Derivados farmaceuticos del anillo heterobiciclico 6,5.

Country Status (10)

Country Link
US (1) US20200399268A1 (es)
EP (1) EP3752150A1 (es)
JP (1) JP2021513976A (es)
KR (1) KR20200121823A (es)
CN (1) CN112105357A (es)
BR (1) BR112020015976A2 (es)
CA (1) CA3090746A1 (es)
MX (1) MX2020008265A (es)
RU (1) RU2020129785A (es)
WO (1) WO2019158731A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
GEP20237572B (en) * 2019-09-25 2023-11-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
CN113024563B (zh) * 2019-12-24 2023-01-03 药康众拓(江苏)医药科技有限公司 嘧啶并五元杂环类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途
PL4097099T3 (pl) 2020-02-07 2024-11-04 Gasherbrum Bio, Inc. Heterocykliczne agonisty glp-1
JP6912016B1 (ja) * 2020-04-10 2021-07-28 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
WO2021205631A1 (ja) * 2020-04-10 2021-10-14 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Method of cancer therapy
KR102513463B1 (ko) * 2020-11-26 2023-03-29 주식회사 에스앤케이테라퓨틱스 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제
AR124443A1 (es) * 2020-12-22 2023-03-29 Novartis Ag Compuestos y composición para el tratamiento de condiciones asociadas con cgas
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT70954A (en) * 1992-04-03 1995-11-28 Upjohn Co Bicyclic-heterocyclic amines containing nitrogen heteroatoms
FR2852957B1 (fr) * 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
WO2006096444A2 (en) * 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
EP1904501A2 (en) * 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemical compounds
KR20140104060A (ko) * 2006-10-19 2014-08-27 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2733143A1 (en) * 2012-11-14 2014-05-21 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma receptors ligands
HK1223358A1 (zh) * 2013-12-20 2017-07-28 吉利德科学公司 作為離子通道調節劑的稠合雜環化合物
JOP20170083B1 (ar) * 2016-04-07 2022-03-14 Glaxosmithkline Ip Dev Ltd أميدات هتيروسيكلية مفيدة كمعدلات بروتين
WO2017175156A1 (en) * 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Also Published As

Publication number Publication date
KR20200121823A (ko) 2020-10-26
BR112020015976A2 (pt) 2020-12-15
WO2019158731A1 (en) 2019-08-22
US20200399268A1 (en) 2020-12-24
JP2021513976A (ja) 2021-06-03
CN112105357A (zh) 2020-12-18
EP3752150A1 (en) 2020-12-23
RU2020129785A (ru) 2022-03-16
CA3090746A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX2020008265A (es) Derivados farmaceuticos del anillo heterobiciclico 6,5.
PH12021551065A1 (en) Fused ring compounds
PH12021500014A1 (en) Fused ring compounds
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
NZ760847A (en) Purified 2,5-furandicarboxylic acid pathway products
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MY192425A (en) Polymorphs
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
PH12016501613A1 (en) Pyrazines modulators of gpr6
PH12020550947A1 (en) Polymorphs
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
WO2017064627A3 (en) Process for preparation of eribulin and intermediates thereof
MX386501B (es) Compuestos terapeuticos y sus metodos de uso
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2
PH12021550320A1 (en) Bicyclic heteroaryl derivatives
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
AR117132A1 (es) Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas
EA201892498A1 (ru) Замещенные карбонуклеозидные производные, приемлемые в качестве противораковых агентов